Physician profile
Omer Khan
NPI 1396036646
$13,468.30
in general payments reported to CMS, 2019-2025
41 companies · $3,036 in 2025
The $3,036 reported for 2025 was more than what 92% of Nephrology (Internal Medicine) providers received nationally (typical 2025 total: $311).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $878 · 2020: $1,548 · 2021: $1,423 · 2022: $2,014 · 2023: $1,885 · 2024: $2,683 · 2025: $3,036.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $7,562 · Education: $42.89.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $7,562.08 |
| Education | $42.89 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Otsuka America Pharmaceutical, INC. | $1,311.01 | 2019-2025 | Jynarque, Voyxact |
| Astrazeneca Pharmaceuticals LP | $961.68 | 2019-2025 | Farxiga, Lokelma |
| Travere Therapeutics, INC. | $949.36 | 2022-2025 | |
| Vifor Pharma, INC. | $902.20 | 2019-2025 | Veltassa |
| Akebia Therapeutics INC | $899.98 | 2019-2025 | Vafseo, Auryxia |
| Bayer Healthcare Pharmaceuticals INC. | $885.89 | 2021-2025 | |
| Calliditas Therapeutics US INC. | $854.74 | 2022-2025 | Tarpeyo |
| Amgen INC. | $841.67 | 2019-2025 | Krystexxa, Tavneos |
| Mallinckrodt Hospital Products INC. | $673.28 | 2020-2025 | Acthar, Terlivaz |
| Opko Pharmaceuticals, LLC | $609.66 | 2019-2025 | Rayaldee |
| Aurinia Pharma U.S., INC. | $577.95 | 2021-2025 | Lupkynis |
| Novartis Pharmaceuticals Corporation | $492.63 | 2019-2025 | |
| Ardelyx, INC. | $457.38 | 2023-2025 | Ibsrela |
| Glaxosmithkline, LLC. | $396.78 | 2019-2025 | Benlysta, Arexvy, Shingrix |
| Fresenius USA Marketing, INC. | $341.50 | 2019-2025 | Velphoro, Velphoro |
Show all 41 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Omer Khan listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.